AGC and Asahi partner for clinical drug production in Seattle
16 Aug 2023
ADC
Preview
Source: Pharmaceutical Technology
AGC Biologics is to produce clinical drugs for antibody-based therapies at its Seattle manufacturing site. Credit: unpict/Shutterstock.com.
AGC Biologics has entered an agreement with Asahi Kasei Pharma to produce clinical drugs for antibody-based therapies at its Seattle manufacturing site.
AGC Biologics will use Asahi’s monoclonal antibody development and manufacturing experience to perform process transfer, process optimisation and clinical manufacture.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Lirafugratinib Hydrochloride in Solid Tumor GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Pimasertib Hydrochloride in Solid Tumor GlobalData
View allCompanies IntelligenceAGC IncAsahi Co LtdAGC Biologics ASAsahi Kasei Pharma CorpView all
Scientists at the Seattle manufacturing site will also support Asahi in submitting regulatory documents, manufacturing the product and preparing it for late-phase procedures.
AGC Biologics chief business officer JB Agnus stated: “Our company has a strong history of antibody production, and we pride ourselves on offering the flexibility and the technical expertise to meet any drug substance need at this critical clinical phase.
“We look forward to partnering with Asahi Kasei Pharma to help achieve their goals with this important project.”
At the Seattle facility, AGC Biologics runs multiple mammalian cGMP manufacturing lines at various scales for mammalian and microbial biologics.
It also serves as a centre of excellence for formulation, and utilises the latest fed-batch and perfusion manufacturing processes.
With a range of biologics products in production, the site recently expanded to add a new microbial-based manufacturing line system.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.